

## **Product datasheet for TR302366**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

#### **POMGNT1 Human shRNA Plasmid Kit (Locus ID 55624)**

#### **Product data:**

**Product Type:** shRNA Plasmids

**Product Name:** POMGNT1 Human shRNA Plasmid Kit (Locus ID 55624)

**Locus ID:** 55624

Synonyms: gnT-I.2; GNTI.2; GnT I.2; LGMD2O; LGMDR15; MEB; MGAT1.2; RP76

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Format:

Retroviral plasmids

Components: POMGNT1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID

= 55624). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

**RefSeq:** NM 001243766, NM 001290129, NM 001290130, NM 017739, NR 024332, NM 017739.1,

NM 017739.2, NM 017739.3, NM 001290130.1, NM 001290129.1, NM 001243766.1,

BC001471, BC001471.2, BM999774, NM 017739.4

UniProt ID: Q8WZA1

Summary: This gene encodes a type II transmembrane protein that resides in the Golgi apparatus. It

participates in O-mannosyl glycosylation and is specific for alpha linked terminal mannose. Mutations in this gene may be associated with muscle-eye-brain disease and several congenital muscular dystrophies. Alternatively spliced transcript variants that encode

different protein isoforms have been described. [provided by RefSeq, Feb 2014]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).